US Department of Defense Reports Final Results from Travelan® Shigellosis Challenge Study
12 juin 2019 07h00 HE
|
Immuron Limited
Key Highlights: Travelan® shigellosis challenge studies in non-human primates successfully completedTravelan® prevented clinical shigellosis (bacillary dysentery) in 75% of Travelan® treated animals...
Immuron sales surge by 66% in the Third Quarter of FY19
15 avr. 2019 09h00 HE
|
Immuron Limited
Key Highlights: Immuron achieved 66% YoY growth in worldwide sales for the third quarter of FY19, ending March 31, 2019.In Australia Q3 sales of Travelan® surged ahead, growing 73% YoY.In the US Q3...
Immuron Aims to Secure FDA Approval for IMM-124E to Prevent Travelers’ Diarrhea
11 avr. 2019 09h00 HE
|
Immuron Limited
Key Points Immuron to develop U.S. registration dossier for IMM-124E for Travelers’ DiarrheaCompany anticipates significant inflection in sales with successful FDA registration of IMM-124ECompany to...
Travelan® FY19 1st Half Update and Geographic Expansion into North America
29 janv. 2019 09h30 HE
|
Immuron Limited
Key Highlights: Immuron achieved 7% YoY growth in worldwide sales for the first half of FY19.In the US, Travelan® exhibited double-digit growth for this period, with sales 10% higher than observed...
US Department of Defense Reports Travelan Protects Against Shigella in Primates
05 sept. 2018 10h00 HE
|
Immuron Limited
Key Highlights: Travelan® pre-clinical shigellosis challenge studies in non-human primates (NHP) successfully completedTravelan® prevented clinical shigellosis (bacillary dysentery) in 75% of...
Immuron’s Travelan® Sales Continue to Soar in Third Quarter of FY2018 in Australian & US Markets
23 avr. 2018 09h30 HE
|
Immuron Limited
Key Highlights: US Travelan® sales continue an upward trend with a 95% increase in the Third Quarter of 2018 compared to the same period last year. YTD US sales (End March 2018) climbed to...
Travelan® Revenue Grows Significantly in US and Australia
16 févr. 2018 09h30 HE
|
Immuron Limited
Key Highlights: Immuron’s flagship product Travelan® reports revenue in excess of AUS$914K for first 6mths of FY2018 Travelan® US experienced a 250% increase in sales year over year reaching...
US Defense Reports Broad Travelan® Reactivity to 180 Pathogenic Bacteria Including Camylobacter and Shigella
29 janv. 2018 09h20 HE
|
Immuron Limited
Key Highlights: The research program was performed by the U.S. Department of Defense (DoD) and was conducted by the Department of Enteric Diseases, Armed Forces Research Institute of Medical Sciences...
Travelan Experiences Strong Q1 FY2018 Sales Growth
08 nov. 2017 09h00 HE
|
Immuron Limited
Key Highlights: Significant growth of sales for Immuron’s over-the-counter supplement Travelan® for Q1 2018 compared to Q1 2017 Travelan® US experienced a 197% increase in sales compared to Q1...